Page 1 of 10

Supporting information

Tyrosine-Derived Stimuli Responsive, Fluorescent Amino Acids

Pradeep Cheruku,^a Jen-Huang Huang,^b Hung-Ju Yen, ^a Rashi S. Iyer,^b Kirk D. Rector,^a Jennifer S. Martinez,^c and Hsing-Lin Wang ^{a, *}

^a C-PCS, Chemistry Division, ^b Defense System and Analysis Division, ^c Center of integrated Nanotechnologies (CINT), Los Alamos National Laboratory, Los Alamos, New Mexico, 87545, United States

*To whom correspondence should be addressed: <u>hwang@lanl.gov</u>

General experimental: All solvents and chemicals were purchased from Aldrich chemicals unless otherwise stated and were used without further purification. Fmoc protected amino acids, coupling reagents and resins were purchased from Novabiochem and used without further purification. Chromatographic separations were performed on Kiesel gel 60 H silica gel (particle size: 0.063-0.100 mm). Thin layer chromatography (TLC) was performed on aluminum-backed plates coated with Kieselgel 60 (0.20 mm, UV254) and neutral alumina visualized under ultraviolet light (v = 254 nm), or by staining with ethanolic phosphomolybdic acid and heating. NMR spectra were recorded on Bruker spectrometers operating at 400 MHz for ¹H and 100 MHz for ¹³C NMR. Chemical shifts are reported in ppm (δ scale) and coupling constants (J) are reported in Hz. Optical rotations were measured with a Jasco P-2000 polarimeter using a 1.0-dm cell.

General procedure for heck coupling: A mixture of the styrene (2.5 mmol), the Boc-3-iodo-L-tyrosine methyl ester or Boc-3,5-diiodo-L-tyrosine (1 mmol), DIPEA (5 mmol), $Pd(OAc)_2$ (5 mol%) and $P(o-tol)_3$ (7 mol%) in anhydrous DMF was stirred under nitrogen at 100 °C for 4-12 h. The reaction was cooled to 25 °C and filtered through celite. The filtrate was collected and evaporated in vacuum. The crude product was purified by column chromatography.

Methyl(R,E)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3-styrylphenyl)propanoate(4a):

(corresponding carboxylic acid analog)

Chromatographed on silica gel (n-hexane/ethyl acetate) to obtain **4a** as light brown solid, yield = 81%; $[\alpha]_D^{25}$: +15 (c = 0.08, methanol); ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.50 (s, 1H), 7.60-7.49 (m, 2H), 7.48-7.31 (s, 2H), 7.30-7.20 (m, 1H), 7.16 (d, *J* = 16.80 Hz, 1H), 7.09-6.93 (m, 1H), 6.90-6.82 (m, 1H), 6.83-6.73 (m, 1H), 4.21-4.09 (m, 1H), 2.94-2.85 (m, 1H), 2.80-2.70 (m, 1H), 1.30 (s, 9H); ¹³C NMR (75 MHz, CDCl₃): δ 171.60, 154.20, 152.71, 139.09, 137.79, 131.04, 129.97, 129.70, 128.61, 127.84, 127.45, 126.57, 123.22, 116.38, 115.17, 85.34, 80.68, 60.60, 28.20; MS (MALDI-TOF): calcd for: C₂₃H₂₇NO₅ = 397.2, observed = 397.1

Methyl(R,E)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3-(4-methoxystyryl)phenyl)propanoate

(4b): Chromatographed on silica gel in n-hexane/ethyl acetate system to obtain 4b as pale yellow solid, yield = 72 %; $[\alpha]_D^{25}$: +16 (c = 0.1, methanol); ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.53 (s, 1H), 7.47 (d, *J* = 7.46, 2H), 7.41 (s, 1H), 7.29-7.18 (m, 2H), 7.10 (d, *J* = 16.65 Hz, 1H), 6.98-6.87 (m, 3H), 6.75 (d, *J* = 8.39 Hz, 1H), 4.21-4.09 (m, 1H), 3.77 (s, 3H), 3.62 (s, 3H), 2.95-2.86 (m, 1H), 2.80-2.70 (m, 1H), 1.30 (s, 9H); ¹³C NMR (75 MHz, CDCl₃): δ 172.76, 159.19, 155.37, 152.59, 130.57, 130.08, 129.13, 128.81, 127.74, 127.48, 124.98, 121.03, 116.12, 114.11, 113.94, 80.26, 55.32, 54.67, 52.34, 37.71, 28.33; MS (MALDI-TOF): calcd for: C₂₄H₂₉NO₆ = 427.2, observed = 427.1

Methyl (R,E)-3-(3-(4-aminostyryl)-4-hydroxyphenyl)-2-((*tert*-butoxycarbonyl)amino)propanoate (4c): A suspension of compound 4d and catalytic amount of Rany-Ni in ethyl acetate/methanol (1:1 v/v) was added hydrazine drop wise and stirred at room temperature until the reaction color turned to green. At this point, some more hydrazine was added and stirred for 10 more min. The reaction mixture was filtered through cilite and washed the celite bed with 1:1 ethyl acetate/methanol. Filtrate and washings were collected and evaporated in vacuo. The obtained solid was purified by column chromatography (n-hexane/ethyl acetate) to yield compound **4c** as yellow solid in 87 % yield. $[\alpha]_D^{25}$: +11 (c = 0.08, methanol); ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.38 (s, br, 2H), 7.21 (d, *J* = 8.26 Hz, 1H), 7.00 (d, *J* = 16.9 Hz, 1H), 6.90-6.78 (m, 3H), 6.75-6.71(m, 2H), 6.57 (d, *J* = 8.24 Hz, 2H), 4.21-3.80 (m, br, 1H), 4.50-3.70 (m, br, 3H), 3.40 (s, 3H), 2.95-2.86 (m, 1H), 2.80-2.70 (m, 1H), 1.30 (s, 9H); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 170.00, 155.60, 153.32, 152.59, 148.90, 130.54, 128.98, 128.70, 128.56, 127.66, 126.67, 126.06, 124.70, 118.67, 115.77, 114.51, 78.39, 55.22, 37.78, 28.62; MS (MALDI-TOF): calcd for: C₂₃H₂₈N₂O₅ = 412.2, observed = 412.3

Methyl (R,E)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3-(4-nitrostyryl)phenyl)propanoate (4d):

Chromatographed on silica gel in n-hexane/ethyl acetate system followed by the crystallization in CH₂Cl₂ to obtain **4d** as orange-yellow solid, yield = 72 %; $[\alpha]_D^{25}$: +10 (c = 0.13, methanol); ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.85 (s, 1H), 8.22 (d, *J* = 8.90, 2H), 7.80 (d, *J* = 8.90, 2H), 7.63 (d, *J* = 16.56 Hz, 1H), 7.52 (s, 1H), 7.35 (d, *J* = 8.90, 2H), 7.27 (d, *J* = 8.03 Hz, 1H), 7.07-7.00 (m, 1H), 4.22-4.10 (m, 1H), 3.62 (s, 3H), 2.98-2.86 (m, 1H), 2.84-2.72 (m, 1H), 1.32 (s, 9H); ¹³C NMR (75 MHz, CDCl₃): δ 173.15, 155.85, 154.80, 146.40, 145.19, 131.13, 129.09, 128.67, 128.10, 127.40, 126.06, 124.59, 123.09, 116.35, 78.73, 55.87, 52.18, 36.27, 28.62; MS (ESI): calcd for: C₂₃H₂₆N₂O₇ = 442.2, observed = 442.3

Methyl (R,E)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3-(4-(trifluoromethyl)styryl)phenyl)

propanoate (4e): Chromatographed on silica gel in n-hexane/ethyl acetate system to obtain **4e** as pale yellow solid, yield = 86 %; $[\alpha]_D^{25}$: +15 (c = 0.1, methanol); ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.80 (s, 1H), 8.55-8.49 (m, 2H), 7.64 (d, *J* = 16.56, 1H), 7.54-7.43 (m, 3H), 7.27 (d, *J* = 8.16 Hz 2H), 7.18 (d, *J* = 16.65 Hz, 1H), 7.06-6.99 (m, 1H), 6.80 (d, *J* = 8.27 Hz, 1H), 4.23-4.11 (m, 1H), 3.62 (s, 3H), 3.01-2.83 (m, 1H), 2.84-2.69 (m, 1H), 1.32 (s, 9H); ¹³C NMR (75 MHz, CDCl₃): δ 173.14, 155.86, 154.74, 150.49, 150.07, 145.36, 130.98, 130.61, 130.25, 128.80, 128.20, 127.19, 125.66, 122.97, 121.05, 116.31, 78.75, 55.93, 36.31, 31.16, 28.63; MS (ESI): calcd for: C₂₄H₂₆F₃NO₅= 465.2, observed = 465.2

Methyl(R,E)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3-(2-(pyridin-4-yl)vinyl)phenyl)

propanoate (4f): Chromatographed on silica gel in n-hexane/ethyl acetate system to obtain 4 as pale yellow solid, yield = 72 %; $[\alpha]_D^{25}$: +12 (c = 0.1, methanol); ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.81 (s, 1H), 8.56-8.55 (m, 2H), 7.64 (d, *J* = 16.59, 1H), 7.54-7.44 (m, 3H), 7.27 (d, *J* = 8.13 Hz, 1H), 7.18 (d, *J* = 16.59 Hz, 1H), 7.06-6.99 (m, 1H), 6.80 (d, *J* = 8.13 Hz, 1H), 4.22-4.10 (m, 1H), 3.62 (s, 3H), 2.99-2.84 (m, 1H), 2.84-2.69 (m, 1H), 1.32 (s, 9H); ¹³C NMR (75 MHz, CDCl₃): δ 173.13, 155.87, 154.73, 150.50, 145.37, 130.98, 128.82, 128.62, 128.21, 125.69, 122.98, 121.06, 116.34, 78.74, 55.86, 52.19, 36.28, 28.61; MS (ESI): calcd for: C₂₂H₂₆N₂O₅ = 398.2, observed = 398.4

Methyl (*R*)-2-((*tert*-butoxycarbonyl)amino)-3-(4-hydroxy-3,5-di((*E*) styryl) phenyl) propanoate (5a): Chromatographed on silica gel in n-hexane/ethyl acetate system to obtain **5a** as pale yellow foam, yield = 70%. $[\alpha]_D^{25}$: +8 (c = 0.1, methanol); ¹H NMR (400 MHz, DMSO-*d₆*): δ 7.57-7.49 (d, *J* = 8.75, 4H), 7.41 (s, 2H), 7.40 (d, *J* = 16.20, 2H), 7.35 (d, *J* = 8.05, 1H), 7.09 (d, *J* = 16.20, 2H), 6.96 (d, *J* = 8.75, 5H), 4.22 (m, 1H), 3.78 (s, 6H), 3.65 (s, 3H), 3.03-2.63 (m, 2H), 1.30 (s, 9H); ¹³C NMR (75 MHz, CDCl₃): δ 172.53, 155.42, 150.26, 148.21, 137.66, 137.62, 131.28, 130.89, 129.09, 128.98, 128.51, 128.46, 128.12, 128.09, 127.37, 126.97, 126.89, 126.57, 126.09, 125.83, 123.14, 122.82, 120.76, 80.39, 77.56, 54.82, 52.64, 52.60, 37.90, 28.63; MS (MALDI-TOF): calcd for: $C_{31}H_{33}NO_5 [M + H]^+ = 499.2$, observed = 499.1

Methyl(*R*)-2-((*tert*-butoxycarbonyl)amino)-3-(4-hydroxy-3,5-bis((*E*)-4-methoxystyryl)phenyl)

propanoate (5b): Chromatographed on silica gel in n-hexane/ethyl acetate system to obtain **5b** as pale yellow solid, yield = 52 %; $[\alpha]_D^{25}$: +10 (c = 0.1, methanol); ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.55 (br, 1H), 8.96 (br, 1H), 7.53 (d, *J* = 8.75 Hz, 4H), 7.41 (s, 2H), 7.40 (d, *J* = 16.40, 2H), 7.13 (d, *J* = 8.37, 1H), 7.08 (d, *J* = 16.40, 2H), 6.97 (d, *J* = 8.75, 4H), 4.14 (m, 1H), 3.78 (s, 6H), 3.06-2.69 (m, 2H), 1.32 (s, 9H) (corresponding carboxylic acid analog); ¹³C NMR (75 MHz, CDCl₃): δ 172.59, 159.45, 149.55, 130.66, 135.50, 130.39, 130.16, 129.74, 129.23, 128.10, 127.81, 127.82, 127.74, 126.36, 125.68, 120.65, 114.15, 114.09, 80.03, 55.33, 54.65, 52.30, 37.79, 28.33; MS (MALDI-TOF): calcd for: C₃₂H₃₅NO₇ = 545.2, observed = 545.1

Methyl(R)-3-(3,5-bis((E)-4-aminostyryl)-4-hydroxyphenyl)-2-((tert-butoxycarbonyl)amino)

propanoate(5c): A suspension of compound **5d** and catalytic amount of Rany-Ni in ethyl acetate/methanol (1:1 v/v) was added hydrazine drop wise and stirred at room temperature until the reaction color turned to green. At this point, some more hydrazine was added and stirred for 10 more min. The reaction mixture was filtered through cilite and washed the celite bed with 1:1 ethyl acetate/methanol. Filtrate and washings were collected and evaporated in vacuo. The obtained solid was purified by column chromatography (n-hexane/ethyl acetate) to yield compound **5c** as yellowish green solid in 80 % yield. $[\alpha]_D^{25}$: +8 (c = 0.1, methanol); ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.75 (s, 1H), 7.55-7.10 (m, 10H), 6.93 (d, *J* = 16.20, 2H), 6.56 (d, *J* = 8.17, 4H), 5.32 (br, 4H), 4.31-4.13 (m, 1H), 3.65 (s, 6H), 3.05-2.86 (m, 1H), 2.85-2.68 (m, 1H), 1.30 (s, 9H); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 172.30, 155.87, 150.00, 148.96, 129.22, 129.15, 127.91, 126.97, 126.68, 125.85, 124.63, 118.14, 114.40, 78.70, 55.86, 52.25, 31.18, 28.59; MS (MALDI-TOF): calcd for: C₃₁H₃₅N₃O₅ = 529.2, observed = 529.1

Methyl (*R*)-2-((*tert*-butoxycarbonyl)amino)-3-(4-hydroxy-3,5-bis((*E*)-4-nitrostyryl)phenyl)propanoate (5d): Chromatographed on silica gel in dichloromethane/methanol system and precipitated in dichloromethane to obtain 5d as orange solid solid, yield = 40%, $[\alpha]_D^{25}$: +12 (c = 0.1, methanol); ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.60 (s, 1H), 8.27 (d, *J* = 8.75, 4H), 7.85 (d, *J* = 8.75, 4H), 7.81 (d, *J* = 16.57, 2H), 7.62 (s, 2H), 7.38 (d, *J* = 8.02, 1H), 7.34 (d, *J* = 16.37, 2H), 4.32-4.22 (m, 1H), 3.65 (s, 3H), 3.05-2.97 (m, 1H), 2.88-2.79 (m, 1H), 1.30 (s, 9H); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 173.12, 155.88, 152.39, 146.54, 144.92, 129.65, 128.66, 128.16, 127.60, 126.81, 125.35, 124.59, 78.73, 55.67, 52.27, 36.36, 28.56; MS (ESI): calcd for: C₃₁H₃₁KN₃O₉ = 629.2, observed = [M + H+K]⁺ = 629.4

Sodium 4,4'-((1E,1'E)-(5-((R)-2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxo propyl)-2-hydroxy-1,3-phenylene)bis(ethene-2,1-diyl))dibenzenesulfonate(5e): After the reaction, solvents were evaporatedand the obtained solid was re-dissolved in small amount of DMF and added to 1:1 acetone-methanolmixture. The precipitated was filtered and the obtained solid was washed with 1:10 water/methanolmixture. Obtained as a mixture of 5e and the starting material 4-vinylbenzenesulfonate. 10 mg of crude mixture was further purified by size exclusion chromatography (SEC) using Bio-Gel P-2 gel purchased from Bio-Rad to obtain relatively pure **5e** (purity between 85-90% confirmed by ¹H NMR) as off white powder (whitish fluffy solid after lyophilization). $[\alpha]_D^{25}$: +15 (c = 0.1, water), ¹H NMR (400 MHz, DMSO d_6): δ 8.20 (d, J = 8.40, 4H), 7.86 (d, J = 16.43, 2H), 7.79 (d, J = 8.40, 4H), 7.55 (s, 2H), 7.38 (d, J = 8.02, 1H), 7.33 (d, J = 16.43, 2H), 4.38-4.22 (m, 1H), 3.64 (s, 3H), 3.15-2.97 (m, 1H), 2.90-2.76 (m, 1H), 1.30 (s, 9H); ¹³C NMR (75 MHz, DMSO- d_6): δ 172.60, 155.45, 150.32, 148.22, 137.76, 137.65, 131.38, 130.92, 129.19, 129.09, 128.55, 128.56, 128.22, 128.21, 127.47, 127.01, 126.87, 126.77, 126.19, 126.01, 123.14, 123.02, 120.76, 80.39, 77.56, 54.82, 52.64, 52.72, 38.00, 28.73; MS (ESI): calcd for: C₃₀H₃₀NNaO₁₁S = 667.1, observed = [M + H]⁺ = 668.1 (corresponding carboxylic acid)

Methyl(R)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3,5-bis((E)-2-(pyridin-4-yl)vinyl)phenyl)

propanoate(5f): Chromatographed on neutral alumina in dichloromethane/methanol system to obtain **5f** as a yellow solid, yield = 35 %, $[\alpha]_D^{25}$: +12 (c = 0.23, methanol); ¹H NMR (400 MHz, DMSO-*d₆*): δ 9.50 (s, 1H), 8.57 (m, 4H), 7.82 (d, *J* = 16.43, 4H), 7.58 (s, 2H), 7.54 (m, 4H), 7.36 (d, *J* = 16.43, 2H), 7.17 (d, *J* = 16.43 Hz, 2H), 4.30-4.20 (m, 1H), 3.65 (s, 3H), 3.06-2.96 (m, 1H), 1.30 (s, 9H); ¹³C NMR (75 MHz, DMSO-*d₆*): δ 173.16, 155.88, 152.15, 145.11, 129.64, 128.38, 128.16, 126.39, 125.18, 121.26, 78.75, 55.67, 52.32, 36.29, 28.53; MS (MALDI-TOF): calcd for: C₂₉H₃₁N₃O₅ = 501.2, observed [M + H]⁺ = 502.1

4,4'-((1E,1'E)-(5-((R)-2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-2-hydroxy-1,3

phenylene)bis(ethene-2,1-diyl))bis(1-methylpyridin-1-ium)iodide(5g): Compound 5f (1eqiv) was dissolved in anhydrous acetone and added iodomethane (5 equiv) and stirred at room temperature for 1 h. The reaction mixture was heated to 40 °C for additional 3 h and the solvents were removed under reduced pressure. The resulted solid was precipitated in cold diethyl ether to obtain 5g as dark brown solid in a quantitative yield. $[\alpha]_D^{25}$: +10 (c = 0.01, water); ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.84 (d, *J* = 6.43, 4H), 8.27-8.12 (m, 6H), 7.96 (s, 1H), 7.73 (s, 2H), 7.48 (d, *J* = 16.08, 2H), 7.34 (d, *J* = 8.04, 1H), 4.27 (m, 6H), 3.65 (s, 3H), 3.09-2.97 (m, 2H), 1.30 (s, 9H); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 173.04, 155.90, 155.85, 152.97, 145.65, 135.71, 130.79, 124.53, 123.98, 123.92, 78.84, 52.36, 50.54, 47.41, 34.83, 28.53; MS (ESI): calcd for: C₃₁H₃₇N₃O₅ [M + H]⁺ = 532.3, obsd [M + H]⁺ = 532.2

Peptide Synthesis:

General method for SSPS :⁽¹⁾ Sequence ⁽²⁾: W*VPALK (W* = 5b)

Solid-phase peptide synthesis was carried out manually on 0.01mmol scale in a solid phase peptide synthesis vessel having a medium or coarse porosity fritted glass support.



Scheme S1: Solid Phase Synthesis of Peptide 1

The Fmoc-Val-Wang resin was subjected to Fmoc-peptide synthesis using the following conditions:

Swelling: Fmoc-Lys(Boc)-Wang resin (100-200 mesh), 0.61 meq, 0.016 g, 0.01 mmol) was immersed in DCM (10 mL) and swelled for 2h. Drained and washed with DMF (2 x 5 mL)

Fmoc removal: The resin was treated with a solution of 20% piperidine/DMF (5 mL) for 30 min, and then washed with DMF (5 x 5 mL), dichloromethane (5 x 5mL) and DMF (5 x 5 mL).

Capping: The resin was treated with a solution of 20% acetic anhydride/DMF (10 mL) for 30 min and washed with DMF (5 x 5 mL) and dichloromethane (5 x 5mL).

Coupling conditions: An appropriate Fmoc-protected amino acid (3 equiv), HBTU (3 equiv) and DIPEA (8 equiv) in 5 mL DMF was allowed to stand for 10 min, and the resulting solution was added to the resin and agitated for 3 h. The resin was drained and washed with DMF (5 x 5 mL) and dichloromethane (5 x 5 mL) and DMF (5 x 5 mL). When HBTU was used as a coupling reagent to incorporate Fmoc protected **3b** into the peptide in its unprotected phenol form, the reaction did not provide the desired peptide in good yield. Therefore, we chose 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3*H*)-one (DEPBT)^(ref) as a coupling reagent as it is known to mediate amide bond formation without protecting to the hydroxyl group of the amino acids such as serine and tyrosine. Using DEPBT, coupling went smooth obtaining the final peptides in good yields.

Release: The product was cleaved from the solid support by treatment with TFA:H₂O (9:1, v/v, 10 mL) for 3 h. The resin was filtered and washed with TFA (2 x 5 mL) and dichlorormethane (2 x 5 mL). The combined filtrate and washings were removed in vacuo to give the crude peptide, which was dissolved in small amount of TFA and precipitated with *tert*-butyl ether. The precipitate was dissolved in ACN/H₂O (1:1) and lyophilized to obtain relatively pure peptide in 60% overall yield which was further purified by RP HPLC.

HPLC analysis: Waters C18, 5 μ m LC Column100×2mm, 220 and 300 nm (t=0-5min, 90% A, 10% B; t=5-60min, 10% A, 90% B, t=61-70min, 100% B. (A= water, 0.05% TFA, B = methanol). Flow rate = 0.5 mL/min, tR = 45.89 min); MS (ESI): calcd for: C₅₄H₇₂N₇NaO₁₁ = 1017.5, observed = [M + H]⁺ = 1018.3



Figure S1: (a) Absorption, (b) emission spectra, and (c) DLS data of compound 5d: comparison in THF and DMSO



Figure S2: Concentration dependent PL spectra of pyridine analog 5f in DMSO showing the aggregate formation at concentrations higher than 100 nM



Figure S3. Comparison of UV-vis and PL spectra of pyridine analog (5f) in DMSO and THF



Figure S4. UV-vis spectra of pyridine analog (5f) in acetonitrile under neutral, acidic and basic environments



Figure S5. UV-vis and PL spectra of NO₂ analog (5d) in different solvents (solvatochromism)



Figure S6. pH (left) and redox (right) sensitivity of the compound **5b**. UV-vis spectra were recorded using 50 μM and 10 μM solutions respectively



Figure S7: Origin of pH sensitivity for 5b: Structure A (pH 4) is responsible for the blue emission color under acidic conditions whereas structure B and C (pH 9) showed a redshift in emission spectrum due to the extended conjugation and thus responsible for the green emission color



Figure S8: Origin of redox sensitivity for compound 5b



Figure S9: Absorption (left) and emission (right) spectra recorded at pH 2, 7, and 12 for peptide 1

Peptide 1 showed a clear pH dependence of the fluorescence. While the fluorescence spectra for peptide 1 at both pH 2 and 7 are essentially identical, emission color at pH 12 is different. The optical spectra obtained at pH 12 showed an additional peak at 420 nm in UV-vis spectrum and a red-shifted emission maximum, which are attributed to the deprotonated (phenoxide) form of the phenol of the amino acid.



Figure S10: Determination of pKa value for phenol of 5g; titration curve

References:

- 1. Cheruku, P.; Plaza, A.; Lauro, G.; Keffer, J.; Lloyd, J.; Bifulco, G.; Bewley, A. J. Med. Chem. 2012, 55, 735
- 2. Gomez, J. A.; Chen, J.; Ngo, J.; Hajkova, D.; Yeh, I.-J.; Gama, V.; Miyagi, M.; Matsuyama, S. *Pharmaceuticals*, **2010**, *3*, 3594